This week was significant for the Swedish biopharma company Cereno Scientific with respect to its intellectual property rights. Two of its development programs were granted patent protection, the main program CS1 and the preclinical program CS585.
CS1 receives patent in Europe
CS1, which is being developed for the treatment of the rare cardiovascular disease (CVD) pulmonary arterial hypertension (PAH), will soon be evaluated in a Phase II clinical trial. In preparation for the trial, the company has, as of this week, secured patent protection for CS1 in most major global markets, including the US, Japan, Canada and Australia. Following a completed validation and opposition period, the company can now add Europe to the list, as CS1’s first patent family has been granted patents in 15 European countries.
Company CEO Sten R Sorensen recently expressed its satisfaction in a press release:
»It is fantastic to receive our first patent for CS1 in Europe. Together with the markets already granted, this offers a good broad patent protection, which is generally an important factor when looking at the commercial potential of an asset.«
These new patents will contribute to an already broad market exclusivity.
First patent awarded to CS585
The company's intellectual property news this week didn't stop there. Yesterday, Cereno Scientific announced that the first patent in the company's preclinical CS585 program has been granted. The CS585 program includes stable, selective and potent prostacyclin receptor agonists with demonstrated potential to significantly improve mechanisms relevant to selected cardiovascular diseases. The program is currently undergoing a two-year preclinical development program in collaboration with the University of Michigan with the goal of moving to a Phase I clinical trial.
Read more about CS585 here.
Cereno's CEO commented on the significance of this first patent protecting the CS585 program:
»It is very positive that the first patent has been obtained in the preclinical program CS585. This validation of the innovative nature of the research, which is a patent criterion, from one of the world's largest patent offices is very important at all stages of drug development. Our preclinical programs are significant for Cereno's long-term success, and solid patent protection is a very important factor for the future commercialization of the drug candidates.«
The patent granted by the US Patent and Trademark Office (United States Patent and Trademark Office, USPTO), is named Hydroxyeicosatrienoic acid compounds and their use as therapeutic agents,US11111222, and covers an important strategic market for Cereno, specifically the USA. Being granted a patent in one of the world's largest markets is an important external validation of the level of innovation in the CS585 research program.
Increased commercial potential
Overall, the granted patents strengthen the company's position for future commercialization. The strong intellectual property rights, which protect a diversified project portfolio with broad therapeutic potential, will provide Cereno with increased opportunities to increase the commercial value of the company and its drug candidates going forward.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company that BioStock has received funding from..